Chiesi Total Care^SM AND patient support

Photo of a smiling woman in a white lab coat

Chiesi Total Care is a comprehensive support program that provides exceptional service to patients and healthcare providers

A single call to your dedicated Chiesi Total Care team is all it takes, and they will guide you through the process of getting a patient started on MYCAPSSA therapy. The Chiesi Total Care program provides assistance to patients with or without commercial insurance, Medicaid, and Medicare.*

image of Assess patient eligibility, Insurance Assistance and Access to medication

*Please refer to the full Terms and Conditions for additional eligibility requirements.

Patients May Pay as Little as $0 for Their MYCAPSSA Prescription

To be eligible for these programs:

Patient must be enrolled in Chiesi Total Care. (Enrollment and Authorization Form will be mailed to your patient’s home)
Patient must have commercial insurance and a valid prescription for a US FDA-approved indication for MYCAPSSA
Patient must be a resident of the United States or one of its territories

For more information about ordering MYCAPSSA, contact Chiesi Total Care
chiesitotalcare.com
1-833-346-2277

Watch MYCAPSSA Patient Stories

Jim's story of hope

Watch Jim as he talks about life with MYCAPSSA, and the support he's received along the way. Listen as he encourages others with acromegaly to advocate for themselves.

Becky's move to MYCAPSSA

Listen as Becky talks about transitioning to treatment with MYCAPSSA, and how she's made it fit into her everyday life.

Bonnie's story of perseverance

Watch as Bonnie talks about her experience with acromegaly symptoms, and why she decided to switch to treatment with MYCAPSSA.

Resources for You and to Share With Your Patients for Acromegaly Support

DOWNLOAD PRESCRIPTION  FORM

DOWNLOAD PATIENT CONSENT FORM

DOWNLOAD PATIENT BROCHURE

Frequently Asked Questions About MYCAPSSA

MYCAPSSA is an oral somatostatin analog approved for the long-term maintenance treatment of acromegaly in patients who have responded to and tolerated treatment with octreotide or lanreotide.¹

Patients who respond to and tolerate octreotide or lanreotide may be eligible to take MYCAPSSA instead of receiving injections.²

If your patient’s current SSA treatment is effective and tolerable, he or she may be eligible to take oral MYCAPSSA capsules instead of receiving monthly injections.^1,2

The most common side effects of MYCAPSSA are headache, joint pain, nausea, weakness, diarrhea, and excessive sweating.¹ Learn more about possible side effects in our safety profile.

MYCAPSSA is an oral octreotide formulation. MYCAPSSA uses Transient Permeability Enhancer (TPE^®), a cutting–edge technology that allows octreotide to be given as an oral treatment.^1,3 You can learn more about TPE and how MYCAPSSA works here.

Yes, MYCAPSSA was proven to effectively maintain normal IGF-I and growth hormone levels in the majority of patients.^1,4 Learn more about consistent control and the proven benefits of MYCAPSSA here.

GH, growth hormone; IGF-I, insulin-like growth factor 1.

Once MYCAPSSA has been started, evaluate IGF-I, signs, and symptoms, and titrate MYCAPSSA as needed.¹ Majority of patients in clinical trials received a 60–mg dose of MYCAPSSA or higher.^4-6 Once the maintenance dosage of MYCAPSSA is achieved, monitor IGF-I levels and acromegaly signs and symptoms monthly.¹ Encourage patients to keep an open dialogue about how they feel and any potential symptoms they may experience.¹

MYCAPSSA should be taken twice daily, morning and evening. MYCAPSSA should be taken on an empty stomach (1 hour before or 2 hours after a meal) with a glass of water.¹ See dosing information here.

If a patient forgets to take their dose of MYCAPSSA, he or she should not take the missed dose at a later time.⁷ Advise the patient to take the next dose at the scheduled time.⁷ Encourage patients to be open and honest about any difficulties they experience in taking regular doses.

MYCAPSSA will be delivered monthly to your patient’s home or designated location. The Chiesi Total Care^SM team will work with your patient to deliver MYCAPSSA when and where it’s most convenient for them. Your patient should receive a call from the pharmacy to confirm the shipment. Learn more about Chiesi Total Care.

Commercially insured patients can get MYCAPSSA for as little as $0 out of pocket, based on eligibility. The Chiesi Total Care^SM team is here to guide your office and your patients through the process of getting patients started on MYCAPSSA therapy. For more information and for help understanding how MYCAPSSA works with your patient’s insurance plan, call 1-833-346-2277, Monday–Friday, 7:00 AM-7:00 PM CST.

Amryt Assist is now Chiesi Total Care^SM. The Chiesi Total Care team will be there every step of the way to help make accessing, starting, and staying on MYCAPSSA treatment as easy as possible. They will help facilitate communication between your office, your patient, their specialty pharmacy, and their insurance company to make the transition to MYCAPSSA as seamless as possible. Learn more about Chiesi Total Care.

Yes! Your patient’s specialty pharmacy will help them stay on track with their refills of MYCAPSSA. The pharmacy will reach out each month to coordinate a convenient delivery time for each refill. If any questions or issues arise, your office or your patient can always contact the Chiesi Total Care^SM team for further assistance.

Before first use, unopened wallets of MYCAPSSA should be stored in a refrigerator. Be sure not to freeze MYCAPSSA. After the first use for each wallet, opened wallets can be stored at room temperature between 68°F to 77°F (20°C to 25°C) for up to one month. Care should be taken to keep MYCAPSSA in a safe place and always out of the reach of children.¹

MYCAPSSA is an oral form of octreotide, taken twice a day.¹

Somavert^® (pegvisomant for injection) is a subcutaneous injection, self-administered once daily after a physician-supervised initial loading dose.⁸ Somatuline^® Depot (lanreotide) is for deep subcutaneous injection only, initially administered every 4 weeks by a healthcare professional.⁹ Sandostatin^® LAR Depot (octreotide acetate) and Signifor^® LAR (pasireotide) are intramuscular injections, administered monthly by a healthcare professional.^10,11

Patients who respond to and tolerate octreotide or lanreotide may be eligible to take MYCAPSSA.

^†Somavert^® is a registered trademark of Pfizer Inc.
^‡Somatuline Depot is a registered trademark of Ipsen Pharma S.A.S.
^§Sandostatin^®is a registered trademark of Novartis Pharmaceuticals Corporation.
^||Signifor^® is a licensed trademark of Recordati Rare Diseases Inc.
^¶Please refer to the full Prescribing Information for each product for full Dosage and Administration information.

Chiesi Global Rare Diseases: Our commitment

Chiesi Global Rare Diseases is committed to helping address wellness within the rare disease community

We strive to provide unmatched support in the lives of people living with rare diseases. We work in close partnership with caregivers, patient communities, healthcare professionals, government authorities, and other stakeholders to help make an impact in the rare disease community. We relentlessly pursue sustainable development goals with passion, courage, teamwork, and innovation. We believe—from timely and accurate diagnoses to receiving treatments and finding supportive communities—that no one should feel alone.

Learn more about Chiesi Global Rare Diseases

REFERENCES: 1. MYCAPSSA [package insert]. Amryt Pharmaceuticals; 2022. 2. Fleseriu M, et al. Pituitary. 2021;24:1-13. 3. Tuvia S, et al. Pharm Res. 2014;31(8):2010-2021. 4. Melmed S, et al. J Clin Endocrinol Metab. 2015;100(4):1699-1708. 5. Fleseriu M, et al. Lancet Diabetes Endocrinol. 2022;10(2):102-111.  6. Samson SL, et al. J Clin Endocrinol Metab. 2020;105(10):1-13. 7. Octreotide. MedlinePlus. Updated September 14, 2020. Accessed November 21, 2023. https://medlineplus.gov/druginfo/meds/a620051.html 8. Somavert [package insert]. Pfizer Inc; 2021. 9. Somatuline Depot [package insert]. Ipsen Biopharmaceuticals Inc; 2019. 10. Sandostatin LAR Depot [package insert]. Novartis Pharmaceuticals Corp; 2021. 11. Signifor LAR for injectable suspension, for intramuscular use [package insert]. Recordati Rare Diseases Inc; 2020.

Chiesi Total Care Terms and Conditions

These terms and conditions apply to the patient support services offered through the Chiesi Total Care Patient Support Program (the “Program”) for MYCAPSSA, unless otherwise noted. These patient support service programs may include affordability solutions support, appeals support, benefit verification, patient education support, copay assistance, patient assistance, and Pharmacist support. Patient support services offered through the Program are subject to change.

A patient who receives health care benefits under any plan or program funded in whole or in part by federal or state governments including Medicare, Medicare Part D, Medicare Advantage, Medigap, Medicaid, TRICARE, Veterans Affairs (VA), Department of Defense, State Prescription Assistance Plans (SPAPs) (other than health insurance for federal government employees) or any state health care program such as Medicaid, Children's Health Insurance Program, programs funded under Maternal and Child Health Program or programs funded under Social Services Block Grant (collectively, “Government-funded Plans”) are not eligible for patient support services that provide financial support through the Program. Only patients with commercial insurance who have a valid prescription for a US Food and Drug Administration-approved indication for MYCAPSSA are eligible for patient support services that provide financial support through the Program.

To enroll in any of the patient support services of the Program, the patient must also enroll in Chiesi Total Care. The patient must be a resident of the US or one of its territories.If the Patient is incapable of acting on their own behalf or if the Patient is under 18 years old, enrollment into the Program may be completed by another person acting on their behalf (such as a parent or legal guardian).

If at any time a patient begins receiving prescription drug coverage under any Government-funded Plan, the patient will no longer be able to participate in the patient support services programs that provide financial support through the Program and the patient must notify the Program to stop participation.

Patients residing in or receiving treatment in certain states may not be eligible for the Copay Assistance Program. Patients may not seek reimbursement for value received from Copay Programs. The Copay Programs do not obligate the use of any specific medication or health care provider. Participation in a Copay Program is not conditioned on any past, present, or future purchase.

To determine financial eligibility for participation in the Patient Assistance Program, the patient will be asked to provide the size of the household, annual household income, and proof of income. Proof of income may include, among other things, W2 form(s), paycheck stubs, and/or prior year tax returns.

Other programs may be offered to eligible patients from time to time. Chiesi Total Care will notify the patient of programs for which they are eligible.

Program benefits may not be sold, purchased, traded, or offered for sale, purchase, or trade. The Chiesi Total Care patient support services are not valid where prohibited by law, taxed, or otherwise restricted. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. This is not health insurance.

This is a voluntary program. Patients who choose not to enroll in any of the support programs will still be able to receive medication. Patients may participate in Chiesi Total Care without participating in a support program. After enrolling in Chiesi Total Care, participants may opt out by contacting Chiesi Total Care, as outlined in the Chiesi Total Care Enrollment and Authorization Form. Patients must renew their eligibility by December 31 of each year to continue to receive support under the Program.

By participating in the Program, participants acknowledge that they understand and agree to comply with these Terms and Conditions.